...
首页> 外文期刊>European review for medical and pharmacological sciences. >Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study
【24h】

Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study

机译:慢性内脏痛的药理学方法。专注于羟考酮控释:一项开放的多中心研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Objectives: Visceral pain is a significant issue for patients, and the importance of treating pain is underestimated. New opioid formulations, the primary treatment option for moderate-to-severe pain, have been shown to be effective, but no studies have been conducted to address the efficacy of these agents for visceral pain. This study was conducted to determine the incidence of visceral pain in patients with uncontrolled moderate-to-severe pain, and to evaluate the efficacy of con-trolled-release (CR) oxycodone in this context. Materials and Methods: In this multicenter, prospective, observational study, 967 of 980 evaluated patients were included, 350 (36.2%) of whom presented mainly visceral pain. In most cases (57.0%), patients had experienced pain for <3 months, and the majority (94.9%) were cancer patients. Pain was uncontrolled in 340 (97.1%) patients, and was rated as severe in >2/3 of patients (mean numerical rating scale (NRS) value 7.04 +- 1.68). Patients with uncontrolled pain were given oxycodone CR; all completed the 15-day study and no patient was switched to an alternative opioid. Results: Oxycodone CR was associated with significant reductions in mean NRS value at day 3, 7 and 15 (final mean NRS 2.37 +- 1.59) and the proportion of patients experiencing severe pain had decreased by the end of the study to 1.5%. The SF-12 questionnaire showed significant improvements in quality of life in all domains, and oxycodone CR was well tolerated. Conclusions: Oxycodone CR appears to be a very well tolerated and effective treatment for patients with visceral pain.
机译:背景与目的:内脏疼痛对患者来说是一个重要问题,而治疗疼痛的重要性却被低估了。新的阿片类药物制剂是中度至重度疼痛的主要治疗选择,已被证明是有效的,但尚未进行任何研究来解决这些药物对内脏痛的功效。这项研究的目的是确定中度至重度失控患者内脏痛的发生率,并评估在这种情况下控释(CR)羟考酮的疗效。资料和方法:在这项多中心,前瞻性,观察性研究中,纳入980名评估患者中的967名,其中350名(36.2%)主要表现为内脏痛。在大多数情况下(57.0%),患者经历了小于3个月的疼痛,并且大多数(94.9%)是癌症患者。 340名患者(97.1%)的疼痛不受控制,并且> 2/3的患者被定为严重疼痛(平均数字量表(NRS)值为7.04±1.68)。疼痛未得到控制的患者接受了羟考酮CR治疗;所有患者均完成了为期15天的研究,并且没有患者改用其他阿片类药物。结果:羟考酮CR与第3、7和15天的平均NRS值显着降低(最终平均NRS 2.37 +-1.59)有关,到研究结束时,经历剧烈疼痛的患者比例已降低至1.5%。 SF-12调查表显示所有领域的生活质量都有显着改善,羟考酮CR耐受性良好。结论:羟考酮CR对于内脏痛患者似乎是一种很好的耐受性和有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号